Roche and ARIUS Research Inc. announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.
ARIUS, a Toronto, Ontario based developer of a proprietary antibody platform called FunctionFIRST, which rapidly identifies and selects antibodies based on their functional ability to affect disease before progressing into clinical development. The FunctionFIRST platform will allow Roche to further strengthen its developmental portfolio, initially within the areas of oncology and inflammatory diseases where this new technique offers potentially broad therapeutic applications.
The whole story can be read here.
No comments:
Post a Comment